Register
Forgot your password?

Quadruple therapy for heart failure with reduced ejection fraction of the systemic right ventricle and tricuspid regurgitation in a child

Authors: Vishnyakova I.A.1, Minaev A.V.1, Kovalev I.A.2, Danilov T.Yu.1

Company: 1 Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation
2 Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the N.I. Pirogov Russian National Research Medical University, Moscow, Russian Federation

For correspondence:  Sign in or register.

Type:  Case reports


DOI: https://doi.org/10.24022/1997-3187-2025-19-2-249-256

For citation: Vishnyakova I.A., Minaev A.V., Kovalev I.A., Danilov T.Yu. Quadruple therapy for heart failure with reduced ejection fraction of the systemic right ventricle and tricuspid regurgitation in a child. Creative Cardiology. 2025; 19 (2): 249–256 (in Russ.). DOI: 10.24022/1997-3187-2025-19-2-249-256

Received / Accepted:  10.03.2025 / 20.03.2025

Keywords: transposition of the great arteries Mustard’s operation atrial switch technique chronic heart failure congenital heart disease



Subscribe 🔒

 

Abstract

Transposition of the Great Arteries (d-TMA) is a congenital heart defect with unrelated lung and systemic circulation. More than 90% of infants die without surgical treatment in the first year of life. Anatomical correction is the “gold standard”, however, atrial switch technique (Mustard or Senning procedure) can be used in selected patients. The long-term result of the atrial switch procedure is characterized by the development of heart failure with a decrease of systemic right ventricular function, tricuspid valve insufficiency, cardiac arrhythmias, etc. These complications may occur in childhood, but medication and its features remain unclear. This paper presents a case of successful quadruple therapy in chronic heart failure with reduced ejection fraction of the systemic right ventricle in a child after Mustard procedure, followed by successful tricuspid replacement.

References

  1. Khairy P. Sudden cardiac death in adults with transposition of the great arteries and systemic right ventricles: preventing (night) MAREs. Eur. Heart J. 2022; 43 (28): 2695–2697. DOI: 10.1093/eurheartj/ehac228
  2. Sabbah B.N., Arabi T.Z., Shafqat A., Abdul Rab S., Razak A., Albert-Biotons D.C. Heart failure in systemic right ventricle: mechanisms and therapeutic options. Front Cardiovasc. Med. 2023; 9: 1064196. DOI: 10.3389/fcvm.2022.1064196
  3. Golukhova E.Z., Kim A.I., Zavalikhina T.V., Nefedova I.E., Chernogrivov A.E., Avakova S.A. Analysis for medical care to children with congenital heart disease in Russian Federation and precondition for Registry in the era of digital medical information systems. Creative Cardiology. 2023; 17 (3): 315–321 (in Russ.). DOI: 10.24022/1997-3187-2023-17-3-315-321
  4. Bevilacqua F., Pasqualin G., Ferrero P., Micheletti A., Negura D.G., D’Aiello A.F. et al. Overview of long-term outcome in adults with systemic right ventricle and transposition of the great arteries: a review. Diagnostics (Basel). 2023; 13 (13): 2205. DOI: 10.3390/diagnostics13132205
  5. Mee R.B.B. Severe right ventricular failure after Mustard or Senning operation. Two-stage repair: pulmonary artery banding and switch. J. Thorac. Cardiovasc. Surg. 1986; 92 (3): 385–390.
  6. Minaev A.V. Features of repaired biventricular conotruncal heart defects in adults. The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2019; 20 (4): 324–333 (in Russ.). DOI: 10.24022/1810-0694-2019-20-4-324-333
  7. Duncan B.W., Poirier N.C., Mee R.B., Drummond-Webb J.J., Qureshi A., Mesia C.I. et al. Selective timing for the arterial switch operation. Ann. Thorac. Surg. 2004; 77: 1691–1696.
  8. Jaggers J.J., Cameron D.E., Herlong J.R., Ungerleider R.M. Congenital Heart Surgery Nomenclature and Database Project: transposition of the great arteries. Ann. Thorac. Surg. 2000; 69 (4 Suppl): 205–235. DOI: 10.1016/s0003-4975(99)01282-5
  9. George E.S., Christian B., Pipina B., Juan V.C., Eduardo C., Luca D.C. et al. Clinical guidelines for the management of patients with transposition of the great arteries with intact ventricular septum. Eur. J. Cardio-Thorac. Surg. 2017; 51 (1): 1–32. DOI: 10.1093/ejcts/ezw360
  10. Parker N.M., Zuhdi M., Kouatli A., Baslaim G. Late presenters with dextro-transposition of great arteries and intact ventricular septum: to train or not to train the left ventricle for arterial switch operation? Congenit. Heart Dis. 2009; 4 (6): 424–432. DOI: 10.1111/j.1747-0803.2009.00352.x
  11. Lacour-Gayet F., Piot D., Zoghbi J., Serraf A., Gruber P., Mace L. et al. Surgical management and indication of left ventricular retraining in arterial switch for transposition of the great arteries with intact ventricular septum. Eur. J. Cardiothorac. Surg. 2001; 20: 824–829.
  12. Akilov Kh. A., Pirnazarov Zh.T., Alimov A.B. Optimization of diagnostic protocol for congenital heart defects accompanied by emergencies based on analysis of in-hospital mortality. Children’s Heart and Vascular Diseases. 2024; 21 (1): 30–40 (in Russ.). DOI: 10.24022/1810-0686-2024-21-1-30-40
  13. Apkhanova T. V., Baryshnikova I. Yu., Boсkeria L. A. Transposition of the great arteries. Clinical guidelines 2024. The Ministry of Health of the Russian Federation. Moscow; 2024 (in Russ.).
  14. Jonas R.A., Giglia T.M., Sanders S.P., Wernovsky G., Nadal-Ginard B., Mayer J.J. et al. Rapid, two-stage arterial switch for transposition of the great arteries and intact ventricular septum beyond the neonatal period. Circulation. 1989; 80: 203–208.
  15. Yacoub M.H., Radley-Smith R., Maclaurin R. Two stage operation for anatomical correction of transposition of the great arteries with intact ventricular septum. Lancet. 1977; 1: 1275–1278.
  16. Nakazawa M., Oyama K., Imai Y., Nojima K., Aotsuka H., Satomi G. et al. Criteria for two-staged arterial switch operation for simple transposition of great arteries. Circulation. 1988; 78: 124–131.
  17. Boriskov M. V., Tkachenko I. A. Evolution of surgery for transposition of the great arteries. Children’s Heart and Vascular Diseases. 2022; 19(1): 5–12 (in Russ.). DOI: 10.24022/1810-0686-2022-19-1-5-12
  18. Baryshnikova I.Yu., Sharipov R.A., Kalashnikov S.V., Nefedova I.E., Berishvili D.O., Bockeria L.A. Ventricular function in newborns with simple transposition of the main arteries before and after arterial switch operation. Children’s Heart and Vascular Diseases. 2022; 19 (3): 206–212 (in Russ.). DOI: 10.24022/1810-0686-2022-19-3-206-212
  19. Ansari R.M., Yarmohammadi H., Gareb B., Voors A.A., van Melle J.P. Long-term outcome of patients with transposition of the great arteries and a systemic right ventricle: a systematic review and meta-analysis. Int. J. Cardiol. 2023; 389: 131159. DOI: 10.1016/j.ijcard.2023.131159
  20. Koolbergen D.R., Ahmed Y., Bouma B.J., Scherptong R.W., Bruggemans E.F., Vliegen H.W. et al. Follow-up after tricuspid valve surgery in adult patients with systemic right ventricles. Eur. J. Cardiothorac. Surg. 2016; 50 (3): 456–463. DOI: 10.1093/ejcts/ezw059
  21. Minaev A.V., Podzolkov V.P., Danilov T.Y., Chiaureli M.R., Bupe M.M., Dontsova V.I. Improved surgical outcomes in adults with congenital heart disease and decompensated heart failure: the role of perioperative medical optimization. Am. J. Case Rep. 2023; 24: e939230. DOI: 10.12659/ajcr.939230
  22. Danilov T.Yu., Minaev A.V., Malinkin I.A., Zemlyanskaya I.V. Replacement of both atrioventricular valves in an adult patient with corrected transposition of the great arteries and decompensated heart failure with a reduced ejection fraction. Grudnaya i Serdechno-Sosudistaya Khirurgiya. 2023; 65 (1): 101–105 (in Russ.). DOI: 10.24022/0236-2791-2023-65-1-101-105
  23. Loss K.L., Shaddy R.E., Kantor P.F. Recent and upcoming drug therapies for pediatric heart failure. Front. Pediatr. 2021; 9: 681224. DOI: 10.3389/fped.2021.681224
  24. Fusco F., Scognamiglio G., Merola A., Iannuzzi A., Palma M., Grimaldi N., Sarubbi B. Safety and efficacy of sacubitril/valsartan in patients with a failing systemic right ventricle: a prospective single-center study. Circ. Heart Fail. 2023; 16 (2): e00984. DOI: 10.1161/circheartfailure.122.009848
  25. Zandstra T.E., Nederend M., Jongbloed M.R., Kiès P., Vliegen H.W., Bouma B.J. et al. Sacubitril/valsartan in the treatment of systemic right ventricular failure. Heart. 2021; 107: 1725–1730.
  26. Egorova A.D., Nederend M., Tops L.F., Vliegen H.W., Jongbloed M.R.M., Kiès P. The first experience with sodium-glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure. ESC Heart Fail. 2022; 9 (3): 2007–2012. DOI: 10.1002/ehf2.13871
  27. Neijenhuis R.M.L., Nederend M., Jongbloed M.R.M. et al. The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease. Front Cardiovasc. Med. 2023; 10: 1093201. DOI: 10.3389/fcvm.2023.1093201
  28. Saef J., Sundaravel S., Ortega-Legaspi J., Vaikunth S. Safety and treatment experience with sodium/glucose cotransporter-2 inhibitors in adult patients with congenital heart disease. J. Card. Fail. 2023; 29 (6): 974–975. DOI: 10.1016/j.cardfail.2023.03.011
  29. Neijenhuis R.M.L., MacDonald S.T., Zemrak F., Mertens B.J.A., Dinsdale A., Hunter A. et al. Effect of sodium-glucose cotransporter 2 inhibitors in adults with congenital heart disease. J. Am. Coll. Cardiol. 2024; 83 (15): 1403–1414. DOI: 10.1016/j.jacc.2024.02.017
  30. Ndiaye J.F., Nekka F., Craig M. Understanding the mechanisms and treatment of heart failure: quantitative systems pharmacology models with a focus on SGLT2 inhibitors and sex-specific differences. Pharmaceutics. 2023; 15 (3): 1002. DOI: 10.3390/pharmaceutics15031002
  31. Newland D.M., Law Y.M., Albers E.L., Friedland-Little J.M., Ahmed H., Kemna M.S., Hong B.J. Early clinical experience with dapagliflozin in children with heart failure. Pediatr. Cardiol. 2023; 44 (1): 146–152. DOI: 10.1007/s00246-022-02983-0
  32. Abdul R.K., Doughan M.E., Wendy M.B. Effect of beta blockers (carvedilol or metoprolol XL) in patients with transposition of great arteries and dysfunction of the systemic right ventricle. Am. J. Cardiol. 2007; 99 (5): 704–706. DOI: 10.1016/j.amjcard.2006.10.025
  33. Galves R., Da Costa A., Pierrard R., Bayard G., Guichard J.B., Isaaz K. Impact of β-blocker therapy on right ventricular function in heart failure patients with reduced ejection fraction. A prospective evaluation. Echocardiography. 2020; 37 (9): 1392–1398. DOI: 10.1111/echo.14813
  34. Jhund P.S., Talebi A., Henderson A.D., Claggett B.L., Vaduganathan M., Desai A.S. et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet. 2024; 404 (10458): 1119–1131.
  35. Elsaeidy A.S., Abuelazm M., Ghaly R., Soliman Y., Amin A.M., El-Gohary M. et al. The Efficacy and Safety of Levosimendan in Patients with Advanced Heart Failure: An Updated Meta-Analysis of Randomized Controlled Trials. Am. J. Cardiovasc. Drugs. 2024; DOI: 10.1007/s40256-024-00675-z

About Authors

  • Irina A. Vishnyakova, Resident Physician; ORCID
  • Anton V. Minaev, Dr. Med. Sci., Senior Researcher; ORCID
  • Igor A. Kovalev, Dr. Med. Sci., Professor; ORCID
  • Timur Yu. Danilov, Dr. Med. Sci., Chief Researcher; ORCID

Chief Editor

Elena Z. Golukhova, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, Director of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by